Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia

Acta Biochimica et Biophysica Sinica

Volumn 45, Issue 4, 2013, Pages 259-267

  Liu, Yudong ^a   Zheng, Qixin ^a   Wu, Hongbin ^a   Guo, Xiaodong ^a   Li, Jingfeng ^a   Hao, Shaofei ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

B cell lymphoma 2; Cyclic AMPresponsive element binding protein; Extracellular signalregulated kinase; Osteosarcoma; Rapamycin; Vascular endothelial growth factor A

Indexed keywords

1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC ANTIBIOTIC; CREB1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME INHIBITOR; ISOQUINOLINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; NITRILE; OXYGEN; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; SERINE; SULFONAMIDE; VASCULOTROPIN A;

ARTICLE; CELL HYPOXIA; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; BUTADIENES; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; ISOQUINOLINES; NITRILES; OXYGEN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERINE; SIROLIMUS; SULFONAMIDES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA; RODENTIA;

EID: 84879214020     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmt002     Document Type: Article

References (39)

1. Marina N, Gebhardt M, Teot L and Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9: 422-441.
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K and Kotz R, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002, 20: 776-90.
3. Luan FL, Hojo M, Maluccio M, Yamaji K and Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002, 73: 1565-1572.
4. Wan X, Mendoza A, Khanna C and Helman LJ. Rapamycin inhibits ezrinmediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 2005, 65: 2406-2411.
5. Liu L, Li F, Cardelli JA, Martin KA, Blenis J and Huang S. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 2006, 25: 7029-7040.
6. Medici D and Olsen BR. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1 dependent expression of VEGF. PLoS One 2012, 7: e42913.
7. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ and Blay JY, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012, 30: 78-84.
8. Russell RC, Fang C and Guan KL. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138: 3343-3356.
9. Jacinto E and Lorberg A. TOR regulation of AGC kinase in yeast and mammals. Biochem J 2008, 410: 19-37.
10. Carloni S, Girelli S, Scopa C, Buonocore G, Longini M and Balduini W. Activation of autophagy and Akt/CREB signaling play an equivalent role in the neuroprotective effect of rapamycin in neonatal hypoxia-ischemia. Autophagy 2010, 6: 366-377.
11. Evankovich J, Zhang R, Cardinal JS, Zhang L, Chen J, Huang H and Beer-Stolz D, et al. Calcium/calmodulin-dependent protein kinase IV limits organ damage in hepatic ischemia-reperfusion injury through induction of autophagy. Am J Physiol Gastrointest Liver Physiol 2012, 303: 189-198.
12. Li X, Han X, Llano J, Bole M, Zhou X, Swan K and Anandaiah A, et al. Mammalian target of rapamycin inhibition in macrophages of asymptomatic HIV- persons reverses the decrease in TLR-4-mediated IFN-α release through prolongation of MAPK pathway activation. J Immunol 2011, 187: 6052-6058.
13. Siu YT and Jin DY. CREB - a real culprit in oncogenesis. FEBS J 2007, 274: 3224-3232.
14. Dalle S, Quoyer J, Varin E and Costes S. Roles and regulation of the transcription factor CREB in pancreatic b-cells. Curr Mol Pharmacol 2011, 4: 187-195.
15. Anvekar RA, Asciolla JJ, Missert DJ and Chipuk JE. Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment. Front Oncol 2011, 1: 34.
16. Ferrara N, Gerber HP and LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9: 669-676.
17. Wu D, Zhau H, Huang WC, Iqbal S, Habib FK, Sartor O and Cvitanovic L, et al. cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 2007, 26: 5070-5077.
18. Cifuentes M, Garcia MA, Arrabal PM, Martinez F, Yanez MJ, Jara N and Weil B, et al. Insulin regulates GLUT1-mediated glucose transport in MG-63 human osteosarcoma cells. J Cell Physiol 2011, 226: 1425-1432.
19. Carracedo A, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Eqia A and Sasaki AT, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118: 3065-3074.
20. Testa JR and Bellascosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001, 98: 10983-10985.
21. Wang X, Yue P, Kim YA, Fu H, Khuri FR and Sun SY. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/Raptor inhibition-initiated, mTOR/Rictor-indepenedent Akt activation. Cancer Res 2008, 68: 7409-7418.
22. Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM and Platt JM, et al. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of a-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci USA 2011, 108: 19611-19616.
23. Faivre S, Kroemer G and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5: 671-688.
24. Barbone D, Yang TM, Morgan JR, Gaudino G and Broaddus C. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008, 283: 13021-13030.
25. Anandharaj A, Cinghu S and Park WY. Rapamycin-mediated mTOR inhibition attenuates surviving and sensitizes glioblastoma cells to radiation therapy. Acta Biochim Biophys Sin 2011, 43: 292-300.
26. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB and Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotxicity in breast cancer cells. Caner Res 2004, 10: 7031-7042.
27. Bellis A, Castaldo D, Trimarco V, Monti MG, Chivasso P, Sadoshima J and Trimarco B, et al. Cross-talk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler Thromb Vasc Biol 2009, 29: 1207-1212.
28. Li J, Wang G, Wang C, Zhao Y, Zhang H, Tan Z and Song Z, et al. MEK/ ERK signaling contributes to the maintenance of human embryonic stem cell self-renewal. Differentiation 2007, 75: 299-307.
29. Lu Z and Xu S. ERK1/2 MAP kinases in cell survival and apoptosis. IUBMB Life 2000, 58: 621-631.
30. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H and Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured neurons. Neurosci Lett 2000, 288: 163-166.
31. Jeon SJ, Rhee SY, Seo JE, Bak HR, Lee Sh, Ryu JH and Cheong JH, et al. Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture. Neurosci Res 2011, 69: 214-222.
32. Soulard A, Cremonesi A, Moes S, Schutz F, Jeno P and Hall MN. The rapamycin-sensitive phosphoproteome reveals that TOR controls protein kinase A toward some but not all substrates. Mol Biol Cell 2011, 21: 3475-3486.
33. Shabb JB. Physiological substrates of cAMP-dependent protein kinase. Chem Rev 2001, 101: 2381-2411.
34. Huber A, Bodenmiller B, Uotila A, Stahl M, Wanka S, Gerrits B and Aebersold R, et al. Characterization of the rapamycin-sensitive phosphoproteome reveals that Sch9 is a central coordinator of protein synthesis. Genes Dev 2009, 23: 1929-1943.
35. Laprise P, Lanqlois MJ, Boucher MJ, Jobin C and Rivard N. Down-regulation of MEK/ERK signaling by E-cadherin-dependent PI3K/ Akt pathway in differentiating intestinal epithelial cells. J Cell Physiol 2004, 199: 32-39.
36. Sunayam J, Matscuda K, Sato A, Tachibana K, Suzuki K, Narita Y and Shibui S, et al. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cell. Stem Cells 2010, 28: 1930-1939.
37. Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D and Cordon-Cardo C, et al. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 2007, 67: 7162-7112.
38. Meric-Bernstam F and Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 17: 2278-2287.
39. Ronellenfitsch MW, Brucker DP, Burger MC, Wolking S, Trstschler F, Rieger J and Wick W, et al. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain 2009, 132: 1509-1522.